Story perspectives

Daraxonrasib Doubles Survival in Advanced Pancreatic Cancer

6/3/2026

Summary

Daraxonrasib Doubles Survival

Researchers reported daraxonrasib doubled survival for advanced pancreatic cancer patients versus chemotherapy.
The trial enrolled 500 metastatic patients from the United States, Europe and Asia who had failed chemotherapy.
Daraxonrasib patients lived a median of 13.2 months versus 6.7 months for chemotherapy patients.
Only 1 percent stopped daraxonrasib because of side effects, while 11 percent discontinued chemotherapy.
Researchers submitted the data to the U.S. Food and Drug Administration for possible approval.

Summary

Daraxonrasib Gets Breakthrough

Revolution Medicines announced that daraxonrasib received FDA Breakthrough Therapy Designation in 2025, expediting its review.
Revolution Medicines will file formal approval applications with the FDA and other regulators after publishing Phase 3 results.
Researchers note that the open-label RASolute 302 trial design may bias symptom reporting, but they regard overall-survival results as objective and plan to test the KRAS approach in lung and colorectal cancers.

Summary

Daraxonrasib Reduces Pain

The RASolute 302 trial reported less pain and quality-of-life versus standard chemotherapy.
Annunziata, senior vice president of Extramural Discovery Science at American Cancer Society, warned the drug’s availability hinges on price and insurance.
Former U.S. Senator Ben Sasse said he felt less pain under an FDA-authorized expanded-access for daraxonrasib.
Rash and oral mucositis are side effects, prompting Pancreatic Cancer Action Network case managers to assist patients with searches for daraxonrasib.

1 of 3

Daraxonrasib Doubles Survival

Researchers reported daraxonrasib doubled survival for advanced pancreatic cancer patients versus chemotherapy.
The trial enrolled 500 metastatic patients from the United States, Europe and Asia who had failed chemotherapy.
Daraxonrasib patients lived a median of 13.2 months versus 6.7 months for chemotherapy patients.
Only 1 percent stopped daraxonrasib because of side effects, while 11 percent discontinued chemotherapy.
Researchers submitted the data to the U.S. Food and Drug Administration for possible approval.

1 / 3